Vancouver, British Columbia – December 2, 2024 – TheNewswire – GeneTether Therapeutics Inc. (together with its wholly-owned subsidiary GeneTether, Inc., “GeneTether” or the “Company”) (CSE: GTTX) is providing an update to its shareholders regarding the potential impact of the strike by the Canadian Union of Postal Workers on the Company's ability to comply with its obligations to deliver its meeting materials to shareholders in connection with its upcoming annual general and special meeting of shareholders scheduled to be held on December 12, 2024 (the "Meeting").

The Company has delivered the completed Notice of Meeting, Information Circular and related proxy materials (the "Meeting Materials") to the appropriate parties for mailing to registered and unregistered shareholders prior to the Meeting, but due the postal strike, it is possible that the Meeting Materials will not be delivered to shareholders prior to the Meeting. Shareholders will still be able to vote their shares either directly by proxy (for registered shareholders) or indirectly through their intermediary (for unregistered shareholders who hold their shares through brokerage firms or other intermediaries). Instructions respecting voting can be obtained as outlined below

The Meeting Materials have been filed under the Company's SEDAR+ profile at www.sedarplus.com and are also available at https://odysseytrust.com/client/genetether-therapeutics-inc/.  The Company will provide copies of the Meeting Materials by email to each entitled shareholder who requests them while the strike is ongoing, at no charge.  Shareholders can direct requests for copies of the Meeting Materials to Roland Boivin, President and CEO, at the contact details below or to Odyssey Trust Company's Shareholder Services Call Center at 1-888-290-1175 (toll free within North America) or 1-587-885-0960 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it..

If you are a registered shareholder, please contact at Odyssey Trust Company at 1-888-290-1175 (toll free within North America) or 1-587-885-0960 or email by This email address is being protected from spambots. You need JavaScript enabled to view it. to obtain your proxy form control number to cast your vote for the upcoming AGM.

If you hold shares through an intermediary such as a brokerage firm, please contact your intermediary directly for a copy of the proxy form and instructions for voting.

The Company will also extend the cut-off time for the delivery of proxies to 9:00 a.m. (Eastern time) on December 11, 2024, to allow extra time for shareholders who have not received the Meeting Materials due to the Canada Post strike.

About GeneTether Therapeutics

GeneTether Therapeutics is a CSE-listed biopharmaceutical company based in Kelowna, British Columbia. For more information regarding GeneTether, please visit www.genetether.com and its profile page on SEDAR+ at www.sedarplus.ca. 

Contact:

Roland Boivin, CEO

(833) 294-4363 ext. 1

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Neither the Canadian Securities Exchange nor its Regulation Service has approved nor disapproved the contents of this news release.